Saniona

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

Saniona’s mission is to develop innovative treatments for diseases of the Central Nervous System, focusing on alleviating the suffering of patients and their families.

Our vision is to become the leading developer of drugs for the treatment of CNS diseases.

Saniona has received numerous awards and recognitions, including being recognized as one of the top 50 biotech companies of the year in Denmark , being listed as one of the top 10 emerging European biotech companies by BioPharma , and being recognized as one of the top 100 transforming healthcare companies by Nesta .